| Hua, Lixin |
NCT06350825: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients |
|
|
| Recruiting | 3 | 200 | RoW | Cytoreductive prostatectomy or brachytherapy, surgery or radiation therapy+SOC, ADT+second-generation antiandrogens ± chemotherapy, hormonal therapy or chemotherapy | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Therapy, Directly Observed | 12/27 | 12/28 | | |
NCT06177015: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC |
|
|
| Recruiting | 3 | 200 | RoW | Darolutamide continuous, Darolutamide, Darolutamide intermittent | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy | 12/25 | 12/27 | | |
NCT05956639: Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC |
|
|
| Recruiting | 3 | 100 | RoW | 6-month course of antiandrogen drugs, Rezvilutamide, Long-term course of antiandrogen drugs | The First Affiliated Hospital with Nanjing Medical University | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 12/25 | 12/27 | | |
NCT05983783: Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC |
|
|
| Recruiting | 3 | 200 | RoW | Docetaxel, Rezvilutamide, ADT | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect | 12/25 | 12/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
| Hua, Lixxin |
NCT06177015: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC |
|
|
| Recruiting | 3 | 200 | RoW | Darolutamide continuous, Darolutamide, Darolutamide intermittent | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy | 12/25 | 12/27 | | |
NCT05956639: Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC |
|
|
| Recruiting | 3 | 100 | RoW | 6-month course of antiandrogen drugs, Rezvilutamide, Long-term course of antiandrogen drugs | The First Affiliated Hospital with Nanjing Medical University | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 12/25 | 12/27 | | |
NCT05983783: Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC |
|
|
| Recruiting | 3 | 200 | RoW | Docetaxel, Rezvilutamide, ADT | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect | 12/25 | 12/27 | | |
| Wang, Shangqian |
NCT06350825: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients |
|
|
| Recruiting | 3 | 200 | RoW | Cytoreductive prostatectomy or brachytherapy, surgery or radiation therapy+SOC, ADT+second-generation antiandrogens ± chemotherapy, hormonal therapy or chemotherapy | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Therapy, Directly Observed | 12/27 | 12/28 | | |
NCT06177015: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC |
|
|
| Recruiting | 3 | 200 | RoW | Darolutamide continuous, Darolutamide, Darolutamide intermittent | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy | 12/25 | 12/27 | | |
NCT05956639: Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC |
|
|
| Recruiting | 3 | 100 | RoW | 6-month course of antiandrogen drugs, Rezvilutamide, Long-term course of antiandrogen drugs | The First Affiliated Hospital with Nanjing Medical University | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 12/25 | 12/27 | | |
NCT05983783: Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC |
|
|
| Recruiting | 3 | 200 | RoW | Docetaxel, Rezvilutamide, ADT | The First Affiliated Hospital with Nanjing Medical University | Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect | 12/25 | 12/27 | | |
NCT06504017: FUS-TB VS COG-TB in Small Lesions of Prostate Cancer |
|
|
| Not yet recruiting | N/A | 200 | NA | COG-TB: Cognitive Fusion guided prostate targeted Biopsy, FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy | The First Affiliated Hospital with Nanjing Medical University, Huai'an First People's Hospital | Prostate Cancer | 05/25 | 08/25 | | |
